Increasing Herd Immunity with Influenza Revaccination by Mooring, Eric & Bansal, Shweta
1 
 
 
Increasing Herd Immunity with Influenza Revaccination 
Eric Mooring1,4, Shweta Bansal 1,2,3 
 
1. Department of Biology, Georgetown University, Washington DC 20057, USA 
2. Fogarty International Center, National Institutes of Health, Bethesda MD 20892, USA 
3. shweta@sbansal.com 
4. Current address: Center for Communicable Disease Dynamics, Department of Epidemiology, 
Harvard T.H. Chan School of Public Health, Boston MA 02115, USA 
 
Keywords 
influenza, herd immunity, revaccination, contact network, targeted vaccination, degree 
heterogeneity 
 
Abstract 
Seasonal influenza is a significant public health concern in the United States and 
globally. While influenza vaccines are the single most effective intervention to reduce influenza 
morbidity and mortality, there is considerable debate surrounding the merits and consequences of 
repeated seasonal vaccination. Here, we describe a two-season influenza epidemic contact 
network model and use it to demonstrate that increasing the level of continuity in vaccination 
across seasons reduces the burden on public health. We show that revaccination reduces the 
influenza attack rate not only because it reduces the overall number of susceptible individuals, 
but also because it better protects highly-connected individuals, who would otherwise make a 
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disproportionately large contribution to influenza transmission. Our work thus contributes a 
population-level perspective to debates about the merits of repeated influenza vaccination and 
advocates for public health policy to incorporate individual vaccine histories. 
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Introduction 
 Influenza is a serious public health threat in the United States. In recent decades, seasonal 
influenza has contributed to about 30,000 excess deaths per year on average [1], is a significant 
cause of outpatient and emergency department visits by children [2-3], and accounts for millions 
of lost workdays each year [4]. Controlling influenza is a multifaceted effort utilizing strategies 
such as antiviral drug treatment and prophylaxis [4] and hygiene practices like washing hands 
and wearing face masks [5-6]. However, seasonal influenza vaccination has been the centerpiece 
of influenza control efforts in the United States for the past 60 years and vaccine coverage of 
only 40% is believed to reduce the risk of influenza illness by about 60% among the overall 
population [7]. 
While the impact of overall influenza vaccine coverage levels in a single season has been 
studied in detail [8-12], the consequences of repeated seasonal influenza vaccination to the same 
individuals have not been studied as extensively. Most research on repeated vaccination has 
considered this problem from an immunological [13-14] or purely statistical perspective and not 
considered potential population-level consequences of repeated vaccination. For example, Ohmit 
et al. [15] recently found that seasonal influenza vaccines are ineffective for patients who were 
vaccinated the previous season, but Keitel et al. [16] and Voordouw et al. [17] found that 
repeated vaccination contributes to increased protection. Such discrepancies may be explained by 
the antigenic distance hypothesis, which depends on positive and negative interference between 
vaccine strains [18].  
A thorough understanding of the merits of vaccination strategies may require considering 
their consequences across multiple seasons. Carrat et al. [19] assume no long-term 
immunological benefits from repeated seasonal influenza vaccination, and model long-run 
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effects of vaccination strategies which prescribe vaccinating adults and children, such as the 
strategy recently adopted in the United States. Their analysis suggests that vaccinating people 
throughout their lives prevents them from developing natural immunity to influenza and 
therefore increases the risk of infection at older ages. Counterintuitively, their results suggest that 
given the greater risk of mortality associated with influenza at increasing ages, vaccination at all 
ages may actually increase influenza mortality. However, their analysis does not directly model 
influenza epidemics and does not account for any herd immunity impacts of higher vaccination 
rates or rates of individual-level revaccination. Similarly, Bodewes et al. [20] suggest that 
repeated seasonal influenza vaccination may be disadvantageous because it might prevent 
patients from developing heterosubtypic immunity that could potentially be protective during a 
pandemic [21].  
Mathematical epidemiological models have been used extensively to study vaccination 
and other influenza control strategies, and consider targeted vaccination to minimize morbidity, 
mortality, or economic costs [22-27]. Some mathematical models as well as epidemiological data 
suggest that targeting influenza vaccination towards school-age children may be a preferred 
strategy, as children are the age group most likely to be infected with influenza and to transmit it 
to others [22, 26]. Others have advocated for a strategy that minimizes mortality by targeting 
those most at risk for complications and death [24, 27]. However, most models of influenza 
vaccination have focused on single epidemics and hence not accounted for the rate of 
revaccination (but see Fung et al. [28]). Also, modeling revaccination inherently requires a 
modeling framework such as contact network modeling that explicitly models individual hosts. 
Recent theoretical research using contact network models has shown the significance of 
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modeling epidemics in series, when natural immunity from past epidemics influences future ones 
[29-30]. 
In this study, we consider whether the rate of revaccination, which we define as the 
proportion of first season vaccine recipients who are vaccinated in a successive influenza season, 
may be epidemiologically relevant. We present a two-season mathematical model to explore the 
consequences of influenza revaccination on herd immunity and the mechanisms driving them. 
Our theoretical study suggests that revaccination indeed reduces the public health burden, and 
that this result is robust with respect to variation in contact structure, vaccine efficacy, vaccine 
coverage, vaccine assortativity, and levels of natural immunity. Our work thus contributes a 
population-level perspective to debates about the merits of repeated influenza vaccination and 
advocates for public health policy to incorporate individual vaccine histories. 
 
Results 
We define the rate of revaccination (r) as the proportion of vaccine recipients in one 
influenza season who are also vaccinated in the following season. If vaccination were random 
with respect to previous vaccination status, the expected revaccination rate would be equal to the 
vaccination coverage. Because the expected revaccination rate is a function of the vaccination 
coverage, we additionally define r’ to be the excess revaccination rate, which takes into account 
variable vaccination coverage and measures revaccination beyond the level expected at random. 
(Details in Methods.) However, for almost all of our analyses we will simply use r, because 
vaccination coverage will be held constant. 
To assess the epidemiological relevance of revaccination rates, we present a contact 
network model for two consecutive influenza seasons. In the contact network model, each 
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individual is represented as a node, and influenza-spreading contacts or interactions are 
represented as edges (Figure 1). Prior to the first influenza season, all individuals in the 
population are susceptible to infection. A proportion of this population is protected by pre-season 
vaccination. We assume that vaccine-induced immunity is fully-protective in a season and is 
protective only in the season in which vaccination occurs, but that natural immunity confers 
protection in the season following infection (further information in Methods). Outbreaks are 
simulated until a large epidemic (i.e. ≥5% of individuals infected) occurs. Following a first 
season epidemic, vaccination is implemented again prior to the second season outbreak. The 
identity of the second season vaccine recipients is chosen based on the revaccination rate (r, 
ranging from 0% to 100%), and is implemented randomly. We assume that the level of 
vaccination coverage is constant across both seasons, supported by the National Health Interview 
Survey which shows that flu vaccination coverage in the United States has been quite consistent 
from the 2007-2008 season to the 2011-2012 season [31]. We record results from second seasons 
in which a large epidemic occurs. We focus on the size of second-season epidemics, because the 
rate of revaccination inherently cannot have any bearing on first season outbreaks. 
 When the model is applied to a synthetic (computationally-generated) exponential 
random contact network (details in Methods below), we find that second season epidemic sizes 
decrease as the rate of revaccination increases (Figure 2). This result indicates that the rate of 
revaccination is indeed epidemiologically relevant, and we explore below some of the 
mechanisms leading to this effect. 
 
Explaining the Effect of Revaccination: “Wasting” Vaccine 
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 One possible cause of the effect of revaccination on epidemic size is that as the rate of 
revaccination increases, vaccine is used more efficiently because individuals with natural 
immunity from first-season infection are less likely to also be vaccinated for the second season. 
When revaccination is complete (r = 100%), no individual can be both naturally immune (i.e. 
protected due to first season infection) and have second-season vaccination because, under total 
revaccination, all individuals vaccinated immediately prior to the second season must have also 
been vaccinated and thus fully protected for the first season. Under the assumptions of the 
model, vaccinating individuals with natural immunity does not provide further protection to 
those individuals or in terms of herd immunity to the population. As a result, more revaccination 
leads to fewer susceptible individuals prior to the second season, which indicates a more efficient 
use of vaccine. 
 We test this by comparing the results of two models that differ only in terms of which 
individuals are eligible to be vaccinated for the first time prior to the second season. One 
model—universal vaccination—follows the method outlined in the previous section, in which 
vaccine doses not used for revaccination are randomly given to any individuals not vaccinated 
for the first season, including both naturally immune and never vaccinated or infected 
individuals. An alternative model—preferential vaccination—still implements revaccination as 
before, but the only individuals who are candidates for first-time vaccination prior to the second 
season are those without natural immunity from the first season, thus not “wasting” vaccine on 
any naturally-immune individuals. While this approach may not be realistic because individuals 
who are infected with influenza in a previous season might be more motivated to be vaccinated 
in a subsequent season, it provides a useful model for comparison. When revaccination is 
complete (r = 100%), no individuals are vaccinated for the first time prior to the second season 
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and, as such, the two models are functionally identical. Figure 3a confirms that under the 
preferential vaccination scenario, the proportion of all individuals who are susceptible prior to 
the second season does not change even as the revaccination rate changes. This is as expected, 
because under the preferential vaccination scenario, the number of susceptible individuals is 
simply the total number of individuals in the network minus the number of individuals with 
natural immunity from the first season and minus the number of individuals vaccinated for the 
second season. Neither first season epidemic size nor vaccine coverage are functions of the 
revaccination rate. 
On the other hand, we find that as the rate of revaccination increases, the proportion of 
susceptible individuals infected during the second season decreases regardless of whether 
individuals with natural immunity are vaccinated (Figure 3b). While the effect of revaccination is 
most pronounced in the universal vaccination scenario, a decrease in epidemic size is also 
evident under the preferential vaccination scenario. This result suggests that the increasing 
number of protected individuals does not fully explain the relationship between revaccination 
rate and epidemic size, and that higher revaccination rates also confer greater indirect protection 
to susceptible individuals. We present these two models of vaccination only to illustrate that 
revaccination has an impact on epidemic sizes even when the number of susceptible individuals 
is constant. Elsewhere in this study we focus only on the universal vaccination approach. 
 
Efficiency of Vaccination Schemes: Connectivity of Susceptible Individuals 
It is well-understood that public health measures such as vaccination can demonstrate an 
impact beyond those directly protected, to indirectly protect a larger community. The extent of 
this indirect protection, or herd effect, can be quantified in our model by comparing second-
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season epidemic sizes at elevated rates of revaccination to second-season epidemic sizes when 
the level of revaccination is equal to the overall coverage level (Figure 4), which is the level of 
revaccination expected if vaccination was not affected by previous vaccination status. Figure 4 
shows that as revaccination increases, the population level efficacy of indirect protection 
increases as well. 
To better understand why higher rates of revaccination indirectly protect susceptible 
individuals, we explore the degree (number of contacts or edges) of susceptible and protected 
(vaccinated or naturally immunized) individuals in the network. Vaccination in the first season is 
random, so the expected value of the average degree of nodes vaccinated in the first season is 
equal to the mean degree of the network (Figure 5a). However, infection during the first season 
and, therefore, natural immunity prior to the second season are not random with respect to 
degree, because higher degree nodes are more likely to be infected during the first season (Figure 
5a) [32, 30]. Consequently, remaining susceptible nodes have disproportionately lower degree, 
on average, than both naturally immune individuals and individuals vaccinated during the first 
season (Figure 5a). In a population connected as an exponential random network, with complete 
revaccination, susceptible individuals in the second season have an average degree that is 15% 
smaller than that of susceptible individuals in the first season. However, when individuals 
vaccinated for the first season are not revaccinated, these nodes of average degree are, in effect, 
added to the set of nodes susceptible in the second season, thereby increasing the average degree 
of susceptible individuals (Figure 5b). This, in turn, decreases the strength of the herd effect in 
the network, because when high degree nodes are not protected either by vaccination or natural 
immunity, the epidemic is able to spread further [33-34]. 
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Robustness in Realistic Populations  
While we are not aware of any studies that focus on estimating influenza revaccination 
rates in large populations, we have been able to infer approximate revaccination rates from a 
variety of studies. Rates likely vary between populations, perhaps depending on factors such as 
access to vaccines and the overall rate of vaccination in the population. For example, data from a 
study of Medicare beneficiaries [35] indicates a revaccination rate of 93.4% between the 1998-99 
and 1999-2000 influenza seasons with a 70% vaccine coverage rate; while Uddin et al. [36] 
surveyed college students and found a revaccination rate between the 2006-07 and 2007-08 
seasons of 58.5% with an average coverage rate of 15.65%. Lastly, based on data reported in a 
large study of people 65 years and older in the Netherlands, we estimated rates of revaccination 
generally between 80 and 90% [17]. Adjusting these revaccination rates for varying coverage 
levels, we estimate plausible excess revaccination rates of 39% to 78% (Figure 6). 
To explore the robustness of our findings, we test our hypotheses on an empirical contact 
network model as well as with realistic values of epidemiological parameters. The empirical 
network represents an urban population based on data for the city of Vancouver, British 
Columbia, and is built from age-specific, activity-based interaction patterns relevant to the 
spread of an influenza-like illness [37, 30]. Bansal et al. [30] find that while the Vancouver-
based model has a higher density of contacts, age-specific contact patterns are captured well in 
the model compared with empirical data from studies on contact structure.  
Based on this contact network, we assume age-specific vaccine efficacy and coverage 
rates based on the 2006 and 2011 influenza seasons in the United States, as well as levels of 
natural immunity based on empirical estimates from recent studies (details in Methods). Our 
findings in this scenario, based on the Vancouver host population and empirical parameters, are 
11 
 
qualitatively similar to those found previously: increased revaccination decreases the proportion 
of individuals infected (Figure 6). While the impact of revaccination is more muted due to the 
use of an imperfect vaccine (as available in the two U.S. influenza seasons considered) with 
moderate levels of coverage, these results illustrate that revaccination does indeed reduce the 
burden on public health (for realistic estimates of r’), and has the capacity for a larger impact. 
In addition, we conduct sensitivity analyses to assess whether our findings are robust with 
respect to partial natural immunity (Figure S1), vaccine efficacy (Figure S2) and vaccine 
coverage rates (Figures S3 and S4). We also studied whether assortative vaccination, a 
phenomenon that has been observed empirically [38, 39], affects the relationship between 
revaccination and epidemic size (Figure S5). In terms of network variables, we consider the 
impact of variation in network size (i.e. the size of the population) (Figure S6) and variance in 
node degree (Figure S7). In general, we find that the decrease in epidemic size due to 
revaccination is strongest when both vaccine efficacy and natural immunity are complete and 
when networks have degree distributions with high variance. In addition, lower vaccine coverage 
appears to increase the effect of revaccination on the total number of cases, highlighting that 
higher revaccination rates can be used to compensate for low coverage rates (e.g. the epidemic 
size for a vaccine coverage rate of 50% with no revaccination is equivalent to the epidemic size 
for a vaccine coverage rate of 30% with full revaccination) (Figure S4). Finally, we observed 
that the relationship between revaccination rate and epidemic size is robust to both assortative 
vaccination and network size. (All figures mentioned are in the Supplementary Materials). 
 
Discussion 
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Using a mathematical modeling framework that accounts for the consequences of past 
epidemics on future disease outbreaks (Figure 1), we have considered the epidemiological 
impact of influenza revaccination. Our work suggests that implementing greater rates of 
revaccination may contribute to reduced outbreak sizes (Figure 2), both by reducing the overall 
number of individuals who are susceptible by using vaccine more efficiently (Figure 3), and by 
increasing the extent to which more connected individuals are protected (Figures 4 and 5). We 
also show that similar results are obtained in populations with more realistic contact structure, 
with empirical estimates of natural immunity levels and less than ideal vaccine coverage and 
efficacy levels from recent influenza outbreaks (Figure 6). While we have focused our attention 
on the impact of revaccination on the total incidence of influenza, we expect similarly positive 
results for other metrics of public health impact (e.g. peak incidence and outbreak duration).  
The process described in this study can be thought of as a partial fragmentation of the 
contact network by first season vaccination and, especially, the random vaccination of highly-
connected individuals. Infection then spreads, working its way through the most connected parts 
of the network, but its path is constrained by first season vaccination. When previously 
vaccinated individuals are not revaccinated (i.e. when r is low), previously protected fragments 
of the network are made vulnerable. This compromises the strength of herd protection, thereby 
creating new paths through the population along which infection during the second season can 
spread, leading to larger second season epidemic sizes. 
More generally, we have demonstrated that mathematical models to develop and test 
influenza vaccination schemes should take into account prior vaccination status, as the 
distribution of vaccination in a population, even if it is random, can shape patterns of natural 
immunity. In turn, patterns of natural immunity are not random and drive the frailty, which is the 
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extent to which highly connected individuals are at risk of infection, of the host population [32, 
30]. These findings also reinforce previous work that highlights the need for shifting influenza 
control strategy with the epidemiological structure of a population, and targeting those most 
likely to be infected [30]. While this study focuses on human influenza in particular, the 
population-level consequences of revaccination rates may be relevant to research on other 
infectious disease systems with complex multi-strain natural and vaccine-induced immunity 
dynamics, such as dengue and even swine influenza or foot and mouth disease in livestock [40-
42]. This study is relevant to public and animal health policy because it contributes a population-
level perspective to debates about the merits of repeated influenza vaccination. 
One of the limitations of this study, however, is that in real populations, there is no 
corresponding first season of seasonal influenza in which natural immunity does not exist, as is 
assumed here. A better understanding of the longitudinal distribution and properties of natural 
and vaccine-induced immunity to influenza in empirical contact networks would significantly 
enhance modeling efforts. Also, this model assumes that the host population is closed and that 
the network structure is constant across both seasons. Presumably those assumptions become less 
tenable as models take into account more seasons in series. However, the mechanism of indirect 
protection we have identified relates to the average connectivity of immune and susceptible 
individuals, not necessarily their particular place in the network. Therefore, future research 
should address not only how contact networks change over time, but also the extent to which the 
degree of individuals remains consistent over time. Finally, this model does not explicitly take 
into account viral evolution (viral evolution is an implicit factor only to the extent that vaccine 
failure is due to antigenic drift). Presumably, the validity of the assumption that vaccine-induced 
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immunity is season-specific and that natural immunity is effective across seasons varies 
depending on the particular pair of seasons under consideration. 
While vaccinating individuals with large numbers of contacts is arguably advantageous 
regardless of the individual’s immunological history, this study indicates that it may be 
especially important to vaccinate individuals who, by virtue of their occupation or living 
arrangements, are likely to have a high number of contacts and who have been vaccinated 
previously. Due to past vaccination, such individuals may be less likely to have natural immunity 
and, if not vaccinated, could infect large numbers of contacts. Some health care systems send 
reminders to people vaccinated in previous years to be vaccinated for the upcoming influenza 
season [43, 35]. Practically, this is an effective practice because past vaccination is a strong 
predictor of future willingness to be vaccinated, but this study shows that this health care 
intervention may have population-level benefits beyond that of simply increasing vaccine 
coverage. The results of our study demonstrate that policy debates about repeated influenza 
vaccination and the related topic of universal vaccination should take into account disease 
ecology and, especially, herd immunity considerations, not just immunological and public health 
implementation considerations. 
 
Methods 
Defining Revaccination 
We define the rate of revaccination (r) as the proportion of vaccine recipients in one 
influenza season who are also vaccinated in the following season. The revaccination rate is 
easiest to conceptualize if populations are closed and the level of vaccine coverage is constant 
across both seasons. As vaccine coverage approaches 100%, the revaccination rate also 
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converges to 100%. However, if the overall vaccination coverage is less than or equal to 50%, 
the range of theoretically possible revaccination rates is 0% to 100%. If vaccination were random 
with respect to previous vaccination status, the expected revaccination rate would be equal to the 
vaccination coverage. To account for this, we additionally define r’ to be the excess 
revaccination rate, which measures revaccination beyond what is expected at random, 
 
r '=
r− C
1− C  
where r is the absolute rate of revaccination and C is the vaccine coverage. 
 
Population Model 
 We simulated epidemics on computationally-generated contact network structures. 
Computationally-generated theoretical networks allow us to systematically study the 
epidemiological consequences of network structure. The network structure used in this study is 
an exponential random network, with the number of contacts (i.e. degree) per individual sampled 
from a geometric distribution, and connected randomly. We assume an average degree of 10 
contacts per individual and a network size of 5,000 nodes. (The impact of these choices is 
studied in the sensitivity analyses.) While much remains unknown about contact networks in real 
populations, Bansal et al. [44] found that contact networks derived from empirical data 
correspond more closely to exponential random network structures than other common network 
types. 
 
Epidemiological Two-Season Model & Vaccination 
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We model first-season vaccination with single doses of influenza vaccine by removing 
select individuals and all their connections from the network. Individuals to be vaccinated are 
chosen randomly, and the size of the population to be vaccinated (and thus fully protected 
against influenza) is CE, where C is the vaccine coverage rate, and E is the vaccine efficacy. We 
call the set of individuals who are vaccinated in the first season, V1, and note that these 
individuals are only protected for the first season (as influenza vaccine-induced immunity is 
temporary). 
To model the first season outbreak, we perform Monte Carlo simulations for a 
susceptible–infected–recovered (SIR) epidemic model with a single initial infected case and per-
contact transmissibility, T1, on all susceptible individuals in the networks specified above. Once 
infected, a node cannot be reinfected during the same season, and unlike with vaccination, will 
have resistance to infection during the subsequent season (natural immunity). This is a 
reasonable assumption because natural immunity is thought to induce a stronger, longer lasting 
immune response than vaccines, and provide better cross-protection across strains [45-48]. 
Second-season vaccination is modeled similarly, except the identity of vaccinated 
individuals is no longer completely random. Based on the revaccination rate, r, a proportion r of 
the vaccinated group (V1) is vaccinated first. The remaining vaccine supply (C-rV1) is distributed 
randomly among the rest of the population. 
The second season outbreak is also modeled with a Monte Carlo SIR model, and an 
independent transmissibility T2. Infection in the second season is allowed in all susceptible 
individuals (that is, those individuals who do not have natural immunity from the first season and 
those who have not been vaccinated immediately prior to the second season). Second season 
outbreaks are only considered in cases when a large epidemic occurs in the first season. The 
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model assumes constant demography and constant network structure over the course of the two 
seasons. Public health burden is measured in terms of the proportion of the population infected in 
the case that there is a large epidemic in the second season (“second-season size of epidemic”).  
 
Realistic Parameters 
In the robustness analysis on the Vancouver urban network [37, 30], we divide the 
population into four age classes: Ages 0-4, 5-18, 19-64, and ≥65. The vaccine efficacies for each 
of these age groups were 60%, 60%, 70%, and 50%, respectively, and were primarily based on 
clinical trials of influenza vaccines and meta-analyses thereof [49-55, 7]. We also implement two 
vaccine coverage scenarios. For a scenario based on the 2011-2012 influenza season in the 
United States, the age-specific vaccine coverage levels are 55%, 45%, 40%, and 70%, 
respectively [56]; for a scenario based on coverage levels from 2006 in the United States, age-
specific vaccine coverage levels are 33%, 16%, 21%, and 65%, respectively [57-58]. 
Revaccination rates are applied to each age class such that the excess revaccination is equal 
across age classes (i.e. differences in vaccine coverage are taken into account.) While the 
relationship between immune response and future protection is not well quantified, the efficacy 
of natural immunity, Q, for all age groups is assumed to be 80% [59-60, 45, 48]. In this case, 
natural immunity is implemented in a manner similar to vaccination, so that 80% of those 
infected in the first season are assumed to be fully protected against infection, while the 
remaining 20% are not protected at all.  
The methods for the remaining sensitivity analyses are described in the Supplemental 
Materials. 
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Figures 
 
Figure 1. Schematic representation of a two-season contact network model for seasonal 
influenza. Individuals make up nodes in the contact network, and contacts between individuals 
are represented by network edges. This heuristic representation assumes that both natural 
immunity and vaccine efficacy are complete (E=1.0 and Q=1.0). The scenario in which there is 
no revaccination (r=0) is illustrated here. The universal revaccination scheme in which naturally 
immune individuals may be randomly selected for second season vaccination is used (note the 
individual, in purple, who is both naturally immune and vaccinated). 
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Figure 2. Second season epidemic size decreases as revaccination increases. This figure is based 
on results from 2000 simulated second season large epidemics on a single 5000 node exponential 
random network with T1=.09, T2=.18, E=1.0, Q=1.0, and C=.25.  
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Figure 3. a) The proportion of all individuals susceptible prior to the second season decreases as 
the revaccination rate increases when the universal vaccination scenario is used (black), but is 
held constant under the preferential vaccination scenario (gray). b) The proportion of susceptible 
individuals infected during the second seasons decreases as the revaccination rate increases 
regardless of whether the universal vaccination scenario (black) or the preferential vaccination 
scenario is used (gray). This figure is based on results from 2000 simulated second season large 
epidemics on a single 5000 node exponential random network with T1=.09, T2=.18, E=1.0, 
Q=1.0, and C=.25. This is the only figure that contrasts results from the universal and 
preferential vaccination schemes. Elsewhere, only universal vaccination is shown. 
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Figure 4. This figure shows the strength of the herd effect (or, indirect protection) at different 
levels of revaccination. Efficacy is calculated as 1-RR, where RR is the relative risk, calculated as 
the ratio of incidence among unvaccinated individuals at the specified rate of revaccination and 
incidence among unvaccinated individuals when the revaccination rate is equal to the vaccine 
coverage (i.e. r’=0). This figure is based on results from 2000 simulated second season large 
epidemics on a single 5000 node exponential random network with T1=.09, T2=.18, E=1.0, 
Q=1.0, and C=.25. 
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Figure 5. a) Estimated probability of first season vaccination is constant regardless of degree 
(black x). Nodes of higher degree are more likely to be infected during the first season epidemic 
and therefore more likely to have natural immunity (black circles). Consequently, lower degree 
nodes are more likely to be susceptible prior to the second season epidemic (gray circles). The 
probabilities shown here are calculated for the 0% revaccination level, but the qualitative 
patterns are similar across all revaccination rates. We note that this panel does not reflect the 
degree distribution of the network. b) At higher revaccination rates, the mean degree of second 
season susceptible nodes decreases. Here, the mean degree of susceptible nodes is normalized by 
the network’s mean degree. This figure is based on results from 2000 simulated second season 
large epidemics on a single 5000 node exponential random network with T1=.09, T2=.18, E=1.0, 
Q=1.0, and C=.25. 
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Figure 6. Second season epidemic size decreases as revaccination increases. This figure shows 
results from 2000 simulated second season large epidemics on an age-structured network 
representative of contact patterns in Vancouver, British Columbia, with partial natural immunity 
(Q=80%) and age-specific vaccine efficacies and coverage rates (see Methods). Two vaccination 
scenarios are illustrated here, one based on vaccine coverage levels in the United States during 
the 2011-2012 influenza season and the other based on vaccine coverage levels circa 2006 in the 
United States. The light gray box corresponds to values of excess revaccination calculated from 
empirical studies of vaccination (see Results).  
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Sensitivity Analysis—Model Variables 
 We conducted numerous simulations to test how changing key parameters in the model 
affected the relationship between revaccination rate and epidemic size. Unless otherwise noted, 
1000 iterations were conducted for each combination of values. We found that when natural 
immunity is stronger, increasing the rate of revaccination has a larger effect on the size of second 
season epidemics (Figure S1). This finding makes intuitive sense because in the limit where 
there is no natural immunity across seasons, each season can be thought of as independent and 
equivalent. As expected, we also found smaller second seasons when natural immunity is 
stronger, regardless of level of revaccination. 
 Additionally, we considered the consequences of changing efficacy of vaccination. The 
effect of revaccination on epidemic size is strongest when vaccine is fully protective (Figure S2). 
Regardless of the degree of revaccination, we found higher second season epidemic sizes when 
vaccine efficacy was greater, because greater vaccine efficacy in the first season limited the 
degree of natural immunity in the second season and vice versa. For this reason, we plotted the 
summed first and second season epidemic sizes. 
 Next, we considered the effect of changing the level of vaccine coverage. This sensitivity 
analysis is complicated by the fact that the level of vaccine coverage is not wholly independent 
of the rate of revaccination. Therefore, we analyzed the effect of changing rates of excess 
revaccination, which is measured as 
r '=
r− C
1− C  
where r is the absolute degree of revaccination and C is the vaccine coverage. This can be 
thought of as the extent of revaccination beyond that which would be expected by chance (C) 
normalized by the magnitude of the range of possible excess revaccination (1-C). Figure S3 
indicates that the effect of revaccination is greater at lower vaccine coverage levels, but this 
effect is largely because at lower vaccine coverage levels, the range of possible excess 
revaccination rates is larger. Specifically, figure S4 plots the same data but plots the absolute 
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revaccination (r) as opposed to the excess revaccination (r’) on the x-axis. The effect of 
increasing revaccination at high vaccine coverage levels now appears magnified. Because the 
degree of vaccine coverage affects the first season epidemic size and hence the degree of natural 
immunity in the population, as with the sensitivity analysis on vaccine efficacy, we plot summed 
first and second season epidemic sizes. 
 Finally, we investigated whether assortativity with respect to vaccination affects the 
relationship between revaccination and epidemic size. There does not appear to be any 
systematic effect on the relationship, but assortativity affects the size of the first season epidemic 
and thus the amount of natural immunity in the community, so we therefore present summed first 
and second season epidemic sizes (Figure S5). 
 Assortative vaccination assignments were generated based on the algorithm of Salathé 
and Khandelwal [1]. Assortative first season vaccination assignments were created by first 
randomly assigning vaccination at a given coverage level and calculating the assortativity 
coefficient ρ. Next, two nodes with opposite vaccination status were selected and their assigned 
vaccination statuses were swapped; ρ was recalculated and if ρ was increased by the swap then it 
was preserved. If not, the pair of nodes reverted to their original assigned vaccination status. This 
process was repeated until the target assortativity was reached. In this sensitivity analysis, target 
assortativities of 0.05, 0.10, 0.15, 0.20, and 0.25 were used. The values span values observed in 
an empirical study of seasonal influenza vaccination on a contact network [2]. To generate 
second season vaccination assignments, the first season assignments and a given level of 
revaccination were used to generate preliminary second season assignments. Then, as before, the 
assortativity was boosted as needed by randomly selecting pairs of nodes with opposite second 
season vaccination status, swapping statuses, and recalculating ρ. But now, all pairs of nodes had 
to share the same first season vaccination status. (This process was unnecessary when 
revaccination was complete, because the first season assignments were reused and already met 
the target level of assortativity.) We did not investigate having the target level of assortativity 
vary between seasons. 
Sensitivity Analysis—Network Variables 
 We conducted simulations to determine the effect of changing the structure of the 
network on the relationship between the degree of revaccination and second season epidemic 
size. To test the effect of network size, we computationally generated exponential random 
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networks with 250, 500, 5,000, 15,000, and 25,000 nodes. While the degree distributions were 
drawn from theoretical distributions with mean degree of 10, the networks actually differ slightly 
in mean degree, which influenced the size of first seasons and, in turn, the extent of natural 
immunity. Therefore, for the same reason as in the assortativity sensitivity analysis, the response 
variable shown in this analysis is the summed first and second season epidemic size. Figure S6 
shows the results of simulations on ten networks of each size. Note that simulations using the 
smaller networks exhibit greater variance in epidemic size. However, there does not appear to be 
a systematic effect of network size on the relationship between revaccination rate and epidemic 
size. 
 Finally, we assessed the effect of changing variance of the degree distribution on the 
relationship between revaccination rate and epidemic size. We computationally generated 
negative binomial networks from negative binomial distributions with mean degree 10 and 
variances 10, 13.5, 18, 22.5, 36, and 90. The negative binomial distributions were shifted 
rightward by one unit so that zero was excluded from the degree distribution. We found that the 
effect of increasing revaccination was strongest when variance in degree was greatest (Figure 
S7). This finding confirms our explanation that non-randomness of natural immunity with 
respect to degree partially underlies the effect of revaccination on epidemic size. Because the 
variance of the degree distribution affects first season epidemic sizes, summed first and second 
season epidemic sizes are plotted in figure S7. 
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Figure S1. When natural immunity is stronger, the effect of revaccination on mean second season 
epidemic size is more pronounced. This figure is based on results from 1000 simulated second 
season large epidemics on a single 5000 node exponential random network with T1=.09, T2=.18, 
E=1.0, and C=.25. Error bars are ± 1 standard deviation. 
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Figure S2. When the efficacy of vaccination is greater, the effect of revaccination on epidemic 
size is more pronounced. This figure is based on results from 1000 simulated second season large 
epidemics on a single 5000 node exponential random network with T1=.09, T2=.18, Q=1.0, and 
C=.25. Error bars are ± 1 standard deviation. 
38 
 
 
Figure S3. When plotted as a function of excess revaccination, lower vaccine coverage appears 
to increase the effect of revaccination on epidemic size, at least for the range of vaccine coverage 
levels simulated here. (However, see figure S4.) This figure is based on results from 1000 
simulated second season large epidemics on a single 5000 node exponential random network 
with T1=.17, T2=.6, E=1.0, and Q=1.0. Error bars are ± 1 standard deviation. 
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Figure S4. This figure plots the same data as figure S3, but as a function of the absolute degree 
of revaccination. Note that the series of points for each vaccine coverage level appear more 
parallel in this figure than in figure S3. This figure is based on results from 1000 simulated 
second season large epidemics on a single 5000 node exponential random network with T1=.17, 
T2=.6, E=1.0, and Q=1.0. Error bars are ± 1 standard deviation. 
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Figure S5. It does not appear that vaccine assortativity, ρ, modifies the relationship between 
revaccination and epidemic size. Each point is based on 2000 simulated first and second season 
epidemics, but unlike in the other model simulations in this article, the same vaccine assignments 
were used for all simulations at each combination of assortativity and revaccination. Epidemics 
were simulated on a single 5000 node exponential random network with T1=.09, T2=.18, E=1.0, 
Q=1.0, and C=.25. Error bars are ± 1 standard deviation. 
41 
 
 
Figure S6. There does not appear to be a major effect of network size on the relationship between 
revaccination and epidemic size. Simulations on ten different networks of each listed size were 
conducted. This figure is based on pooling results from 500 simulations on each exponential 
random network with T1=.09, T2=.18, E=1.0, Q=1.0, and C=.25. Error bars are ± 1 standard 
deviation. 
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Figure S7. When the variance of the degree distribution is greater, the effect of revaccination on 
epidemic size is more pronounced. This figure is based on results from 1000 simulated second 
season large epidemics on each 5000 node, mean degree 10 negative binomial random network 
with T1=.13, T2=.17, E=1.0, Q=1.0, and C=.25. Error bars are ± 1 standard deviation. 
